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Abstract
Background: Kinins play an important role in regulation of pain and hyperalgesia after tissue injury and
inflammation by activating two types of G-protein-coupled receptors, the kinin B1 and B2 receptors. It is generally
accepted that the B2 receptor is constitutively expressed, whereas the B1 receptor is induced in response to
inflammation. However, little is known about the regulatory effects of kinin receptors on the onset of acute
inflammation and inflammatory pain in humans. The present study investigated the changes in gene expression of
kinin receptors and the levels of their endogenous ligands at an early time point following tissue injury and their
relation to clinical pain, as well as the effect of COX-inhibition on their expression levels.
Results: Tissue injury resulted in a significant up-regulation in the gene expression of B1 and B2 receptors at 3
hours post-surgery, the onset of acute inflammatory pain. Interestingly, the up-regulation in the gene expression of
B1 and B2 receptors was positively correlated to pain intensity only after ketorolac treatment, signifying an
interaction between prostaglandins and kinins in the inflammatory pain process. Further, the gene expression of
both B1 and B2 receptors were correlated. Following tissue injury, B1 ligands des-Arg
9-BK and des-Arg
10-KD were
significantly lower at the third hour compared to the first 2 hours in both the placebo and the ketorolac treatment
groups but did not differ significantly between groups. Tissue injury also resulted in the down-regulation of TRPV1
gene expression at 3 hours post-surgery with no significant effect by ketorolac treatment. Interestingly, the change
in gene expression of TRPV1 was correlated to the change in gene expression of B1 receptor but not B2 receptor.
Conclusions: These results provide evidence at the transcriptional level in a clinical model of tissue injury that up-
regulation of kinin receptors are involved in the development of the early phase of inflammation and inflammatory
pain. The up-regulation of B1 receptors may contribute to acute inflammatory pain through TRPV1 activation.
Background
Tissue injury results in the liberation of various pain
and inflammatory mediators; we have reported earlier in
the oral surgery model of acute inflammatory pain the
production or up-regulation of a number of prostanoids,
cytokines and chemokines [1-4] following tissue injury.
Hargreaves and colleagues have also shown an increase
in bradykinin (BK) concentration following third molar
tooth extraction [5]. Further, they showed that the
NSAID flurbiprofen prevented this increase in BK levels.
Bradykinin-related peptides, collectively known as
kinins, are proinflammatory mediators that mediate vas-
cular responses and pain following tissue injury. Kinins
bind to two types of G protein-coupled receptors, the B1
and B2 receptors, both of which have been cloned [6,7].
B1 receptors are activated by the endogenous kinins
lacking the carboxy-terminal Arg residue, namely des-
Arg
9-BK and Lys-des-Arg
9-BK, also known as des-
Arg
10-KD. B2 receptors are activated by the full
sequence of the endogenous kinins BK, and Lys-BK, also
known as kallidin (KD) [8]. B2 receptors are constitu-
tively expressed but undergo extensive desensitization
by their agonists. They are widely distributed and med-
iate most of the biological actions of BK. On the other
hand, B1 receptors are induced during the inflammatory
processes or at least strongly regulated, except in the
spinal cord, where they are constitutively expressed in
both rat and man [9]. Further, B1 receptors are only
subjected to limited desensitization, which make them a * Correspondence: dionner@mail.nih.gov
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any medium, provided the original work is properly cited.better target for analgesics [10,11]. In experimental stu-
dies, the expression of B1 receptors has been reported to
occur in response to the B1 ligand Lys-des-Arg
9-BK [12]
and inflammatory cytokines such as IL-1b and TNF-a
[13-15]. Regulation of B1 expression by B2 receptor
through activation of NFB and MAP kinases has also
been observed [12,15]. However, to our knowledge this
has not been shown in man.
Kinin receptors are expressed in neuronal tissues, are
upregulated in response to painful stimuli and their
antagonists produce an antinociceptive effect in different
pain models [16,17]. Furthermore, B1 receptor knockout
mice are refractory to chemical and thermal nociceptive
stimuli [18]. Transient receptor potential vanilloid 1
(TRPV1) is suggested to mediate ionic mechanisms cou-
pling BK receptors to the excitation and sensitization of
nociceptors [19].
The interaction between prostaglandins (PG) and BK
in the process of inflammatory pain is well established
[20,21] as BK induces prostaglandin release in various
tissues [20,22,23]. It is suggested that BK-induced sensi-
tization is in part secondary to prostaglandin synthesis,
since NSAIDs inhibit BK-mediated sensitization of heat
responses, while prostaglandin E2/I2 reverse this inhibi-
tion [24,25].
The aim of the present study was to investigate the
role of kinin receptors in acute inflammatory pain in
humans by assessing the gene expression of B1 and B2
receptors following oral surgery and its correlation to
self-reported pain intensity, as well as to evaluate the
levels of their immunoreactive ligands at the site of tis-
sue injury using the microdialysis technique. The inter-
action between the kinin system and COX-PG pathway
was also studied.
Results
1. Effect of tissue injury and ketorolac treatment on BK
and des-Arg
9-BK
Both BK and des-Arg
9-BK levels in microdialysate were
detectable at all time points and decreased gradually
over the 3 h collection period with the third hour being
significantly lower than the first and second hours in
both the placebo and ketorolac treatment groups (p <
0.05). However, there was no significant difference
between both treatment groups and Fig. 1 (a&b) shows
t h el e v e l sm e a s u r e da tt h el e f ts i d e .T h er i g h ts i d e
showed the same results (data not shown).
HPLC analysis performed on microdialysate samples
collected at the site of tissue injury from both placebo
and ketorolac treatment groups, showed that kinins
detected by chemiluminescent enzyme immunoassays
were mainly detected at the retention time corresponding
to the reference peptides des-Arg
9-BK (18.6 min), BK
(24.1 min), des-Arg
10-KD (24.7 min) and KD (29.8 min).
2. Effect of tissue injury and ketorolac treatment on
BDKRB1 and BDKRB2 gene expression at the site of tissue
injury
Following the identification of four different immunor-
eactive kinins and their increased levels following tissue
injury, it becomes of interest to test for the expression
of kinin receptors in the same model. Both BDKRB1
and BDKRB2 were significantly upregulated 3 hours fol-
lowing tissue injury in both the placebo and ketorolac
treatment group (Table 1). BDKRB1 was 2.5-fold upre-
gulated in the placebo treated group (p < 0.0001; paired
t-test; n = 15) and 2.4-fold upregulated in the ketorolac
treatment group (p < 0.0001; paired t-test; n = 15).
Similarly, BDKRB2 was 2-fold upregulated in the pla-
cebo treated group (p < 0.0001; paired t-test; n = 15)
and 1.9-fold upregulated in the ketorolac treatment
group (p < 0.0001; paired t-test; n = 15). Ketorolac
treatment did not have a significant effect on the gene
expression of either BDKRB1 (p = 0.71; unpaired t-test)
or BDKRB2 (p = 0.73; unpaired t-test).
3. Correlation between pain intensity and the gene
expression of BK receptors
The contribution of kinins to pain is well established.
Further, the correlation between BK and KD and change
in pain intensity was recently reported in man [26]. We
assessed here whether the gene expression of kinin
receptors was also correlated to pain intensity.
Pain intensity has increased throughout the three hours
observation period (time: p < 0.001), and as expected
ketorolac treatment induced a significant analgesic effect
(p = 0.023; two-way repeated measure ANOVA) over the
three hours observation period (Fig. 2a).
The correlation between the sum of pain intensity
scores as measured by VAS and the up-regulation of
gene expression of BDKRB1 and BDKRB2 following tis-
sue injury was examined using Pearson’sc o r r e l a t i o n
coefficients (Fig. 2 b-e). Both BDKRB1 (r = 0.68; p =
0.005; n = 15) and BDKRB2 ( r=0 . 5 8 ;p=0 . 0 2 ;n=1 5 )
were positively correlated to pain intensity in the ketor-
olac treatment group. On the other hand, BDKRB1 (r =
0.22; p = 0.425; n = 15) and BDKRB2 (r = 0.50; p =
0.058; n = 15) did not significantly correlate to pain
intensity in the placebo treatment group.
4. Effect of tissue injury and ketorolac treatment on
TRPV1 and NFB gene expression at the site of tissue
injury
To investigate the mechanism of B1 receptor up-regula-
tion and the contribution of TRPV1 receptor to the
algesic mechanisms of both kinin receptors, we further
evaluated the gene expression of both TRPV1 and NFB
in the same biopsies and examined the correlation
among the changes in their gene expression levels.
Hamza et al. Molecular Pain 2010, 6:12
http://www.molecularpain.com/content/6/1/12
Page 2 of 11NFB was slightly, though significantly, up-regulated
following tissue injury in both the placebo treated group
(1.3-fold, p = 0.027; paired t-test; n = 15) and the ketor-
olac treatment group (1.4-fold, p = 0.042; paired t-test;
n = 13; Table 1). There was no significant difference
between the two treatment groups (p = 0.56; unpaired t-
test).
On the other hand, TRPV1 was significantly down
regulated following tissue injury in both the placebo
treated group (2.2-fold, p < 0.0001; paired t-test; n = 15)
and the ketorolac treatment group (2.6-fold, p < 0.0001;
paired t-test; n = 15). However, there was no significant
difference between the two treatment groups (p = 0.33;
unpaired t-test).
5. Correlation between the gene expression of BDKRB1,
BDKRB2, TRPV1 and NFB
Since there was no significant difference between
the two treatment groups (placebo and ketorolac) in the
gene expression of either of the four genes studied, the
two treatment groups were pooled to calculate the cor-
relation coefficient for both receptors [4]. The gene
expression of BDKRB1 and BDKRB2 were significantly
correlated (r = 0.52; p = 0.004; n = 30; Fig. 3a). Further,
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Figure 1 The levels of immunoreactive kinins were significantly lower at the third hour compared to the first 2 hours. There was no
significant difference between the placebo and ketorolac treatment groups. Fig. (1a) shows the levels of B2 receptor ligands (BK and KD) and
Fig. (1b) shows the levels of B1 receptor ligands (des-Arg
9-BK and des-Arg
10-KD). Concentrations of immunoreactive kinins (pg/ml) were
transformed into Ln (X+1), which is shown here. For details, please refer to the methods section. Figures show the levels measured at the left
side. The right side showed similar results. Data are presented as mean ± SEM; *indicated p < 0.05, 3 way ANOVA.
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lated to BDKRB1 (r = 0.49; p = 0.006; n = 30; Fig. 3b)
but not BDKRB2 (r = 0.33; p = 0.077; n = 30; data not
shown). On the other hand, the gene expression of
NFB was not correlated to either BDKRB1 (r = -0.106;
p = 0.61; n = 26) or BDKRB2 (r = 0.19; p = 0.35).
Discussion
Kinin levels are very difficult to measure accurately in
biological samples, particularly in blood, due to the pre-
sence of metabolic enzymes that have the capacity to
synthesize or metabolize kinins in vitro. Further, kinins
act locally close to their site of formation before they
are rapidly hydrolyzed [27]. The microdialysis technique
overcomes these difficulties by collecting the kinins at
the site of inflammation and excluding the large mole-
cular weight enzymes that may change kinin levels.
In the present study, and in accordance with previous
studies [5,26], we show an elevation in the tissue levels
of BK and KD following tissue injury. While the chemi-
luminoenzyme immunoassay does not distinguish
between the two peptides, the use of immuno-HPLC
approach showed clearly that both peptides were present
in the microdialysis samples. Since microdialysis sam-
pling in this study started at the completion of third
molar extraction (approximately 30 minutes duration),
and the intervals of sampling was relatively long (1
hour) to allow for sufficient volume of each sample, the
rise of immunoreactive peptide concentration was not
detected, but rather the fall of its concentration 3 hours
following surgery was detected. This is expected since
the concentration of both kinins are rapidly elevated
within 15 min following injury [26].
Further, we show for the first time in an in-vivo
human study, a similar pattern for B1 receptor ligands
(des-Arg
9-BK, des-Arg
10-KD), being elevated following
tissue injury before their levels decrease at the latter
time points. The immuno-HPLC approach provides
evidence for the presence of des-Arg
10-KD, which is the
most potent known human B1 receptor agonist [28].
Most of the earlier studies of acute inflammatory pain
focused on BK and KD due to the impression that the
B1 receptors are only expressed in chronic inflammation
[29]. However, we show here that the B1 receptor is up-
regulated as early as 3 hours following tissue injury in
humans. Further, pre-surgery biopsies showed expres-
sion of both B1 and B2 m R N Ab e f o r ea n yt i s s u ei n j u r y .
This early expression of B1 receptor [30] or even its
constitutive expression [31] has been shown earlier in
some experimental studies. The importance of B1 recep-
tor lies in the role that it plays in maintaining inflamma-
tion in chronic pain states, in contrast to the B2 receptor
that is quickly desensitized. Several mechanisms have
been suggested to induce B1 receptor up-regulation in
response to inflammation. First, it may be cross up-
regulated by activation of B2 receptors [12]. The correla-
tion we show here between the gene expression of B2
and B1 receptor supports this mechanism in the present
clinical model of tissue injury. Second, our earlier study
showed marked up-regulation of IL-1b [1] and TNF-a
[2] following surgery, and TNF-a was densely expressed
on infiltrated inflammatory cells, particularly, on macro-
phages. Given both TNF-a and IL-1b are known to
upregulate B1 receptor both in-vitro [32] and in-vivo
[15], we hypothesize that the up-regulation of both IL-
1b and TNF-a may contribute to the up-regulation of
B1 shown in this study. Finally, our recent study demon-
strates that an inflammatory cascade mediated by IL-6,
IL-8, CCL2, CXCL1 and CXCL2 contributes to the
development of acute inflammation and inflammatory
pain [4]. This cascade may also contribute to the B1
receptor up-regulation since neutrophil influx has been
suggested to contribute to the up-regulation of B1
receptors [15].
The activation of the transcription factor NFBi sa
critical step in up-regulation of B1 receptors that are
Table 1 Gene expression of kinin receptors, TRPV1 and NFB:
Placebo Ketorolac
Pre-surgery
(Average ΔCt)
Post-surgery
(Average ΔCt)
Fold change*
(P value)
Pre-surgery
(Average ΔCt)
Post-surgery
(Average ΔCt)
Fold change*
(P value)
B1receptor
(BDKRB1)
17.4 ± 3.6 16.2 ± 3.6 2.5 ± 0.9
(p < 0.0001)
18.6 ± 3.4 17.4 ± 3.5 2.4 ± 0.8
(p < 0.0001)
B2receptor
(BDKRB2)
14.8 ± 3.0 13.8 ± 2.9 2.0 ± 0.6
(p < 0.0001)
15.6 ± 2.7 14.7 ± 2.7 1.9 ± 0.5
(p < 0.0001)
NFB 17.3 ± 0.6 17.0 ± 0.4 1.3 ± 1.2
(p = 0.027)
17.3 ± 0.5 17.0 ± 0.7 1.4 ± 0.8
(p = 0.042)
TRPV1 18.8 ± 2.9 19.8 ± 2.7 -2.2 ± 0.9
(p < 0.0001)
19.5 ± 2.7 20.7 ± 2.9 -2.6 ± 1.1
(p < 0.0001)
Data are presented as mean ± S.D.; n = 13-15 per group.
*Fold change is calculated as 2
-ΔΔCt, Average ΔCt is the normalized cycle threshold in reference to the endogenous control (18S rRNA). Data were analyzed using
paired t test.
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Figure 2 (a) Pain intensity assessed by 100 mm VAS was lower in the keterolac treatment group (p = 0.023, two way ANOVA); Data
are presented as mean ± SEM. (b-e) The change in gene expression level (RQ) of both B1 and B2 receptors was correlated to pain intensity
(VAS) in the keterolac treatment group but not in the placebo treatment group. The association between the gene expression and pain scale
was examined using Pearson correlation. The y-axis represents the sum of the pain intensity over the first 3 hours post-surgery. The x-axis
represents the relative changes in gene expression (RQ) from qRT-PCR.
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by its own agonists [34] or by activation of B2 receptors
[35]. The small change in NFB gene expression sug-
gests that this may be mediated primarily at the protein
level (i.e. the activation of NFB) and the role of NFB
gene expression is relatively small at the early stage of
this clinical model of tissue injury. However, to confirm
the role of activation of NFB in this model further ana-
lysis at the protein level is warranted. Due to the limited
size of the biopsy, we were unable to conduct the study
at both the protein and the gene expression levels.
The role of kinin receptors and their endogenous
ligands in inflammation and pain is well recognized
(Fig. 4). Not only does activation of B2 receptors on pri-
mary sensory neurons lead, via second messenger path-
ways, to the activation of polymodal nociceptors and
hyperalgesia [29], but bradykinin can also sensitize noci-
ceptors following the release of prostaglandins [22,25].
This might explain the correlation between pain inten-
sity and B2 receptors expression in the ketorolac treat-
ment group but not in the placebo treatment group.
The presence of prostaglandins affects pain intensity,
therefore, confounding the correlation between B2
receptor and pain intensity shown in the absence of
prostaglandins. Prostanoids released in response to tis-
sue injury [1] would contribute to the inflammatory
pain response by activating their receptors on nerve
endings as well as by interacting with mediators released
to sensitize nociceptors. The similar correlation between
B1 expression and pain intensity points to the participa-
tion of B1 receptor in pain processes at this early time
point (3 hours) in contrast to earlier reports [16] confin-
ing the contribution of B1 receptors to nociception to
later time points. While the present data shows only the
gene expression of kinin receptors due to limited biopsy
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Figure 3 (a) The relative changes in gene expression (RQ) from
qRT-PCR of B1 and B2 receptors were correlated. (b) Similarly,
the relative change in gene expression of TRPV1 was correlated to
that of B1 receptor. The relative change in gene expression is
calculated as 2
-ΔΔCt to show the fold increase. In case of TRPV1, the
downregulation is shown as the negative fold change. The
association was examined using Pearson correlation at 3 hours post-
surgery.
Figure 4 Tissue injury results in the production of kinins and
cytokines. Kinins activate both B1 and B2 receptors on nerve
ending and on other cells (possibly, gingival fibroblasts, epithelial
cells or inflammatory cells). The activation of both B1 and B2
receptors leads via different signaling pathways to the production
of IL-6, IL-8 and CLL2, all of which can activate their corresponding
receptors on the sensory nerve endings. Activation of TRPV1 is
thought to mediate kinins effects on sensory neurons and might
possibly mediate their effect on other cells to produce cytokines.
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functional up-regulation of the receptor has been
reported earlier in LPS treated rats [15]. Further, the
correlation between pain intensity and gene expression
level reported here, argues in favor of a functional rela-
tionship between tissue injury and increased BK recep-
tor activation leading to an increase in pain.
Kinin receptors are known to be expressed in different
tissues besides primary sensory neurons. Immunohisto-
chemical studies showed immunoreactivity for both B1
and B2 receptors in epithelial cells, submucosal glands,
fibroblast, vascular smooth muscle, vascular endothelial
cells, and macrophages of human nasal turbinates [36].
Further, B1 and B2 receptor genes are expressed in gin-
gival fibroblasts [37]. Inflammatory cells such as mast
cells also, shows expression of B1 and B2 receptor [38].
Thus, cellular localization of B1 and B2 receptor in the
present study could be gingival fibroblasts, epithelial
cells in oral mucosa or the inflammatory cellular infil-
trate. However, since we did not carry out immunohis-
tochemical studies, we cannot be certain of the cell
types of the kinin receptors in oral mucosa, as qRT-PCR
cannot distinguish the cellular origin of mRNA
expressed.
In gingival fibroblasts, BK up-regulates IL-1b and
TNFa-stimulated IL-6 [39] and IL-8 [40] production.
Several other studies showed an induction of IL-6, IL-8
and CCL2 via activation of B1 or B2 receptors in a vari-
ety of cells [41-47]. Protein kinase C (PKC) signaling
pathway seems to be responsible for BK induced IL-8
production in gingival fibroblasts [40], and PI-PLC and
NF-B signaling pathways are thought to be responsible
for BK increased IL-6 production, in synovial fibroblasts
[47]. As mentioned earlier, we have recently shown a
correlation between the gene expression of IL-6, IL-8
and CCL2 and pain intensity, in the oral surgery model
[4]. Therefore, it is possible that kinins besides activating
B1 and B2 receptors on sensory nerve terminals, also
activate B1 and B2 receptors on gingival fibroblasts or
inflammatory cells inducing the expression of these
cytokines, which contributes to the development of
inflammatory pain.
TRPV1, a non-selective cation channel expressed in a
group of sensory neurons [48], is considered an impor-
tant target of BK signaling pathways to activate sensory
neurons [19]. However, several other tissues express
TRPV1 in humans, including keratinocytes [49], mast
cells [50], synovial cells [51] and dental pulp fibroblasts
[52]. Activation of the TRPV1 results in an increased
release of IL-8 and PGE2 by epidermal keratinocytes
[49], IL-6 [53] and IL-8 [54] by human bronchial epithe-
lial cells and IL-6 by dental pulp fibroblast [52]. Engler
et al. showed an increased gene and protein expression
of IL-6 in cultured synovial fibroblasts from
osteoarthritis (OA) and rheumatoid arthritis (RA)
patients in response to the TRPV1 agonist capsaicin,
suggesting a possible non-neuronal role for TRPV1 in
OA and RA pain [51]. Therefore, it is possible that
TRPV1 represent a target of BK signaling pathways both
to induce cytokines by non-neuronal cells and to acti-
vate sensory neurons. It is suggested that B2 receptor via
PKC signaling pathway activates TRPV1 in neuronal
cells [55]. The activation of TRPV1 by B1 receptors was
also suggested earlier [56,57]. This would pose a plausi-
ble explanation to the correlation between the change in
gene expression of both receptors even with the up-reg-
ulation of B1 and down-regulation of TRPV1.
I nt h ep r e s e n ts t u d y ,w ed i dn o ts e eac o r r e l a t i o n
between B2 receptor and TRPV1 gene expression. The
absence of significant correlation between B2 and
TRPV1 gene expression could possibly reflect the disso-
ciation between gene expression levels and the function-
ality of B2 receptors due to the constitutive nature of B2
receptors and their rapid desensitization. It could also
be due to the contribution of other TRP receptors to
the signaling mechanism of B2 receptors. Recently, using
TRPV1-KO mice, TRPV1-independent mechanisms
were shown to contribute to BK-evoked pain responses
[58], which might include TRPA1 and other ion chan-
nels [59]. The down-regulation of TRPV1 in response to
tissue injury is however, an unexpected finding, given its
pronociceptive role [60]. Yet, the same finding was seen
following spinal cord injury in rat [61], where TRPV-1
receptor gene expression levels were decreased at the
level of spinal cord injury but increased at rostral spinal
cord areas. The up-regulation of TRPV1 is frequently
reported at the spinal level following neuropathic pain
models [61,62]). It is possible that TRPV1 would play
different roles in the periphery or at the spinal level.
In conclusion, we propose here that B1 receptor is
upregulated early following tissue injury in man, possi-
bly in response to kinin activation, and cytokines and
chemokines secretion. B1 receptor activation contributes
to the development of acute inflammatory pain possibly
via the activation of TRPV1.
Methods
Subjects, timeline of clinical procedures and biopsy
collection
Healthy volunteers (n = 59) between 16 to 30 years old
who required extraction of impacted third molars were
included in the present study (Table 2). The protocol
was approved by the Institutional Review Board of the
National Institute of Dental and Craniofacial Research,
National Institutes of Health (NIH). Written informed
consent was obtained from all participants before treat-
ment. Pregnant or lactating females or patients with the
presence of clinical signs of infection or inflammation at
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subjects received intravenous midazolam (4.8 ± 0.5 mg)
and mandibular nerve block with 2% lidocaine (164.6 ±
26.9 mg) with epinephrine 1:100,000 prior to surgery.
For 29 patients, following satisfactory local anesthesia,
two mandibular third molars were extracted and a surgi-
cal difficulty score was assigned for each tooth as fol-
lows: a score of (2) for soft tissue impactions, (3) for
partial bony impactions and (4) for full bony impactions.
After extraction, a microdialysis probe (CMA/20 Micro-
dialysis Probe; CMA/Microdialysis, North Chelmsford,
MA) was placed bilaterally along the buccal aspect of
the mandible, beneath the mucogingival flap elevated for
the surgical procedure. The probe fiber consists of a 10-
mm flexible, nonmetallic, semipermeable dialysis mem-
brane with a molecular cutoff ranging from 3000 to
20,000 Da. The probes were secured to an adjacent
tooth with silk suture and the flap closed in the usual
fashion using 3-0 chromic gut suture. Sterile lactated
Ringer’s solution was pumped at 10 μL/min and samples
collected at 60-min intervals after the completion of sur-
gery, before pain onset. Subjects randomly received
either placebo or ketorolac (30 mg) intravenously 30
min before biopsy or microdialysis sampling. They
remained under observation for the first 3 h after sur-
gery to evaluate pain and adverse events and collect
samples by microdialysis. During the immediate post-
operative period, subjects were allowed one dose of tra-
madol (100 mg) as a rescue medication, if requested,
after 1 h of evaluation. Patients rated their pain intensity
every 20 min for the first 3 postoperative hours using a
100-mm visual analog scale. At the conclusion of the
observation period, the microdialysis probes were
removed. Microdialysis samples were placed on dry ice
after each collection period, and stored at -70°C. For the
other 30 patients, a preoperative 3 mm punch biopsy
was taken from the oral mucosa overlying the impacted
third molar and a second biopsy was taken from a dif-
ferent surgical site 3 hours post-surgery. All biopsies
were immediately frozen in liquid nitrogen and stored at
-70°C until ready for RNA extraction.
Quantitative real-time PCR
Oral mucosal biopsies (n = 60) were used to detect gene
expression using ABI Prism 7900 HT Sequence Detec-
tion System (Applied Biosystems, Foster City, CA) as
described previously [2,3,63]. All reagents were pur-
chased from Applied Biosystems and 2 μgo fD N a s e -
treated RNA was used to synthesize cDNA using ran-
dom primers from the High-Capacity cDNA Archive Kit
according to the manufacturer’s instruction. Polymerase
chain reaction was performed with cDNA template
using the PCR Master Mix with AmpErase UNG.
Sequence-specific primers and TaqMan MGB probes
were purchased from Assays-on-Demand Gene expres-
sion product. Quantification of gene expression was per-
formed in a 20-μL reaction (384-well plate) and each
sample was run in triplicate. The housekeeping gene
18S rRNA was used as endogenous control and negative
controls were processed under the same conditions
without a cDNA template. Data acquisition was con-
ducted using User Bulletin #2 software (v1.6, Applied
Biosystems). The threshold cycle (Ct) of 18S rRNA was
used to normalize target gene expression (ΔCt) to cor-
rect for experimental variations and average ΔCt was
used for comparison of the gene expression in post-sur-
gery tissue versus that in pre-surgery tissue. The relative
change in gene expression calculated as 2
-ΔΔCt was used
to compare different treatment groups.
Quantification of BK and des-Arg
9-BK
Microdialysis samples were diluted in cold absolute
ethanol (1:8 v/v), incubated overnight at 4°C then centri-
fugated. The supernatant was evaporated to dryness and
the residue of evaporation was stored at - 20°C until the
quantification and characterization of immunoreactive
kinins. Residues of evaporated ethanol extracts of micro-
dialysates were resuspended in 50 mM Tris-HCl buffer
pH 7.4, containing 100 mM NaCl and 0.05% Tween-20.
After resuspension, B2 receptor ligands (BK and KD)
and B1 receptor ligands (des-Arg
9-BK and des-Arg
10-
KD) were quantified by competitive chemiluminescent
enzyme immunoassays as previously described [64,65].
These methods have been validated and their analytical
performances were reported. As described earlier, these
immunoassays shows cross reactivity between BK and
KD and between des-Arg
9-BK and des-Arg
10-KD.
Identification of immunoreactive kinins (BK, KD, des-
Arg
9-BK, des-Arg
10-KD) was carried out using HPLC
(Agilent 1100 Series system, Agilent Technologies
Canada, Mississauga, ON, Canada) as described earlier
Table 2 Demographic data of participants:
Microdialysis Biopsies
Treatment Placebo Ketorolac Placebo Ketorolac
Number 15 14 15 15
Age 22.3 ± 3.5 19.2 ± 2.9 19 ± 3.6 18.8 ± 2.6
Gender M/F 5/10 4/10 8/7 10/5
Race
White 5 1 11 21 1
African 3 112
Others 7 222
Difficulty* 7.1 ± 2.1 7.1 ± 1.0 7.5 ± 0.9 7.2 ± 0.9
Rescue Medicine 11 (73%) 7 (50%) 8 (53%) 4 (27%)
* Extraction difficulty is the sum calculated by assigning a score of (2) for soft
tissue impactions, (3) for partial bony impactions and (4) for full bony
impactions. Data are presented as mean ± S.D.
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Page 8 of 11[66]. Briefly, 40 microdialysis samples were pooled, and
extracted with cold ethanol as described above. The
residue of samples was dissolved in 200 μlo f5m M
KH2PO4, pH 3.0, 25% acetonitrile with 1% H3PO4.B K ,
KD, des-Arg
9-BK, des-Arg
10-KD were separated on a 2-
sulfoethyl aspartamide column (PolySULFOETHYL A,
The Nest Group Inc., Southborough, MA, USA) using a
linear gradient of KCl (0-300 mM) in 5 mM KH2PO4
and 25% acetonitrile (v/v) pH 3 for 30 min. Fractions of
1 ml were collected from minutes 15 to 35, evaporated
to dryness before quantification of immunoreactive BK
and des-Arg
9-BK. Retention time of each immunoreac-
tive fraction was compared to that of standard peptides:
des-Arg
9-BK (18.6 min), BK (24.1 min), des-Arg
10-KD
(24.7 min) and KD (29.8 min).
Statistical Analysis
All statistical analyses were conducted using SPSS (v.
16.0, SPSS, Chicago, IL). Paired t-test was used to com-
p a r et h eg e n ee x p r e s s i o ni np o s t - s u r g e r yt i s s u ev e r s u s
that in pre-surgery tissue. The relative change in gene
expression was expressed as 2
-ΔΔCt and was used to
compare the change in gene expression in different
treatment groups by unpaired t-test. Linear regression
analysis was used to examine the association between
the fold changes in gene expression (2
-ΔΔCt)a n dt h e
sum of patient-reported pain scores over the first 3 h
post-surgery as measured by VAS. In the case of down-
regulation, the negative fold change was used. The asso-
ciation among these gene expressed was examined by
Pearson’s correlation coefficients.
The effect of ketorolac treatment on VAS was
assessed using repeated measures two-way ANOVA and
the effect of ketorolac treatment on immunoreactive
kinins was assessed using three-way ANOVA with two
within subject factors (side and time) and one between
subjects factor (treatment). A contrast analysis using t-
tests with Bonferroni adjustment was used to measure
the differences, which were statistically significant. Data
did not follow normal distribution, so was transformed
to ln(x+1). Results were considered significant at p <
0.05.
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